Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) Other Gross PP&E Adjustments (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 1.82% to $14.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Dec 2025, down 1.82% year-over-year, with the annual reading at $14.0 million for FY2025, 1.82% down from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $14.0 million at Harvard Bioscience, up from -$8.4 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $14.2 million in Q4 2024, with the low at -$11.8 million in Q1 2021.
  • Average Other Gross PP&E Adjustments over 5 years is -$3.3 million, with a median of -$7.9 million recorded in 2023.
  • The sharpest move saw Other Gross PP&E Adjustments crashed 256.47% in 2021, then skyrocketed 44.45% in 2023.
  • Over 5 years, Other Gross PP&E Adjustments stood at $10.5 million in 2021, then rose by 14.47% to $12.0 million in 2022, then rose by 9.08% to $13.1 million in 2023, then increased by 8.82% to $14.2 million in 2024, then decreased by 1.82% to $14.0 million in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at $14.0 million, -$8.4 million, and -$8.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.